Free Trial

Hudson Bay Capital Management LP Has $11.66 Million Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals logo with Medical background

Hudson Bay Capital Management LP boosted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 27.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 920,108 shares of the company's stock after buying an additional 200,000 shares during the period. Hudson Bay Capital Management LP owned approximately 0.91% of Day One Biopharmaceuticals worth $11,658,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of DAWN. R Squared Ltd acquired a new stake in Day One Biopharmaceuticals during the fourth quarter worth about $31,000. Tower Research Capital LLC TRC lifted its holdings in shares of Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock worth $135,000 after acquiring an additional 9,603 shares during the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $143,000. KLP Kapitalforvaltning AS bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $150,000. Finally, Optimize Financial Inc bought a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $196,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on DAWN shares. Needham & Company LLC dropped their target price on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Wedbush reissued an "outperform" rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a report on Tuesday, March 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $30.57.

Get Our Latest Analysis on Day One Biopharmaceuticals

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. This trade represents a 8.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares of the company's stock, valued at approximately $473,639.92. This trade represents a 10.50% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,064 shares of company stock worth $251,925. 6.20% of the stock is currently owned by insiders.

Day One Biopharmaceuticals Price Performance

NASDAQ DAWN traded up $0.09 during trading hours on Friday, reaching $6.25. The company's stock had a trading volume of 2,739,476 shares, compared to its average volume of 1,104,977. The firm has a fifty day simple moving average of $7.44 and a 200-day simple moving average of $10.79. The stock has a market cap of $633.51 million, a P/E ratio of -6.07 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a 52 week low of $6.08 and a 52 week high of $16.76.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.11. The firm had revenue of $30.76 million for the quarter, compared to the consensus estimate of $30.28 million. On average, research analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.

Day One Biopharmaceuticals Profile

(Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Featured Stories

Institutional Ownership by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?

Before you consider Day One Biopharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.

While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines